5090792025-04-012025-06-305090792025-04-012025-06-30in-capmkt:OtherExpenses1Memberiso4217:INRxbrli:pureiso4217:INRxbrli:shares509079GUFICBIONOTLISTEDINE742B01025GUFIC BIOSCIENCES LIMITEDMain BoardEquity2025-04-012026-03-312025-08-132025-08-07INRLakhsQuarterlyFirst quarterSingle segmentThe Company's business activity falls within a single operating segment i.e. Pharmaceuticals2025-08-1316:30:002025-08-1318:30:00Not applicable2025-04-012025-06-30UnauditedConsolidated223722500092520002246477000885158000142682000-20127000359968000923360007718900053653000020737360001727410000172741000222000001983700042037000013070400000001307040000130704000000010027800011.31.3001.31.30001. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. <BR> <BR> 2. The above results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 13, 2025. The Statutory Auditors have carried out limited review of the results for quarter ended June 30, 2025. <BR> <BR> 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. <BR> <BR> 4. The Consolidated Financial Results for the quarter and financial year ended June 30, 2025, have been prepared by the Company considering the financials of its wholly owned subsidiaries, Gufic UK Limited and Veira Life FZE, and its subsidiary, Gufic Prime Private Limited. As of June 30, 2025, the Company has not made any investment in Gufic Ireland Limited (“GIL”), incorporated in 2023 with the intention of becoming a wholly owned subsidiary, nor has GIL commenced its business operations; hence, consolidation of its accounts with those of the Company was not required. <BR> <BR> 5. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share. <BR> <BR> 6. The figures for the quarter ended March 31, 2025 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to -date figures up to the third quarter ended December 31, 2024 which were subjected to limited review. <BR> <BR> 7. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.Other Expenses536530000000